Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
10.34
+0.18 (1.77%)
At close: Dec 5, 2025, 4:00 PM EST
10.32
-0.02 (-0.19%)
After-hours: Dec 5, 2025, 5:01 PM EST

Company Description

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.

The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index.

Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others.

The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017.

Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics, Inc.
Entrada Therapeutics logo
Country United States
Founded 2016
IPO Date Oct 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 183
CEO Dipal Doshi

Contact Details

Address:
One Design Center Place, Suite 17- 500
Boston, Massachusetts 02210
United States
Phone 857 520 9158
Website entradatx.com

Stock Details

Ticker Symbol TRDA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001689375
CUSIP Number 29384C108
ISIN Number US29384C1080
Employer ID 81-3983399
SIC Code 2834

Key Executives

Name Position
Dipal Doshi Chief Executive Officer and Director
Nathan J. Dowden President and Chief Operating Officer
Dr. Natarajan Sethuraman Ph.D. President of Research and Development
Kory James Wentworth CPA Chief Financial Officer and Treasurer
Dr. Jared Cohen J.D., Ph.D. General Counsel
Karla MacDonald Chief Corporate Affairs Officer
Kevin Healy Ph.D. Senior Vice President of Regulatory Affairs
Sandeep Basnet Head of Information Technology

Latest SEC Filings

Date Type Title
Dec 3, 2025 EFFECT Notice of Effectiveness
Nov 25, 2025 SCHEDULE 13G Filing
Nov 21, 2025 144 Filing
Nov 18, 2025 SCHEDULE 13D/A Filing
Nov 14, 2025 144 Filing
Nov 14, 2025 SCHEDULE 13G/A Filing
Nov 6, 2025 S-3 Registration statement under Securities Act of 1933
Nov 6, 2025 10-Q Quarterly Report
Nov 6, 2025 8-K Current Report
Aug 14, 2025 SCHEDULE 13G/A Filing